On 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
Metsä Group started up its bioproduct mill
Latest NewsFinnish Metsä Group has started its mill for bio-based products. The €1.2bn investment’s production capacity is 1.3 million tonnes of softwood pulp a year.
Oxford Immunotec value drops after public offering
Latest NewsUK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc’s share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million ordinary shares at Nasdaq underwritten by BTIG LLC.
Cleaning up the oceans
BackgroundFrench green chemistry pioneer, Carbios SA (Clermont-Ferrand) announced in March that it has secured equity financing of €2.5m from Kepler Cheuvreux through the acquisition of 380,000 shares over 24 months.
Mundipharma pays US$250 for CAP7.1
Latest NewsGerman CellAct GmbH has cashed in US$250m (€212m) from Mundipharma in a licence deal for CAP7.1, a Phase II drug to treat the rare biliary tract cancer.
Orchard Therapeutics appoints Mark Rothera as CEO
AppointmentsGene therapy specialist Orchard Therapeutics (London) has appointed Mark Rothera as President and Chief Executive Officer, a specialist for the commercialisation of novel treatments and business development.
IP: Brexit and patents
OpinionOn 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
Sepsis: Adrenomed receives approval for POC study in patients with early septic shock
Latest NewsGermany is the first country that has granted full approval to Adrenomed to conduct a Phase II study with the monoclonal antibody adrecizumab in patients with early septic shock. Within the ADR-02 study, 300 patients will be enrolled in Germany, Belgium, France and the Netherlands for proof of safety and efficacy.
CDPQ acquires stake in Sebia
Latest NewsCaisse de dépôt et placement du Québec (CDPQ) is set to acquire a minority stake in diagnostic electrophoresis player Sebia Group from private equity investors Astorg and Montagu.
Swiss Roivant bags US$1.1bn financing
Latest NewsSerial drug licensee Roivant Sciences GmbH (Basel) has cashed in US$1.1bn (€937m) in an equity financing led by SoftBank Vision Fund and co-financed by existing investor Dexcel Pharma.
Voluntary health agency jump-starts Selvita’s SEL120 programme
Latest NewsThe Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukaemia (AML).